Hi Everyone,
I'm new to this group. My Dad has CLL with a B-PLL transformation in his lymph nodes. He has good genetic markers (TP53 unmutated, 17P undeleted) but is IGHV unmutated.
We have two CLL experts who propose different treatment plans for first-line therapy:
1) Monotherapy Ibrutinib or Acalabrutinib
2) Combination therapy Gazyva and Venetoclax
We know that treatment 2 is fixed in duration and holds promise for disease clearance for an indeterminate period of time but with a need for retreatment. We also know that choice one is "tried and true" but for an indeterminate about of time until retrearment is needed.
To add to the complexity:
- There is such little information about B-PLL treatment.
- There is no head to head clinical trial between the two plans.
- There are no NCCN guideline for standard first-line care, particularly for transformed PLL.
Yet, we know that sequencing of meds is critical to control this disease.
I ask for your personal experience or research, so our family makes an informed decision on the best course to take for my dad's transformed CLL. I know this group can help us or point us in the right direction.
Thank you for your time, care, and help.